Literature DB >> 12142374

Tumor-associated trypsin inhibitor.

Ulf-Håkan Stenman1.   

Abstract

Tumor-associated trypsin inhibitor (TATI) is a low-molecular-weight (6 kDa) trypsin inhibitor that has been used as a marker for ovarian cancer. It is also expressed together with tumor-associated trypsin by many other tumors, and increased serum concentrations of TATI occur in connection with these. TATI is a prognostic marker for ovarian, bladder, and kidney cancer, which may be associated with the participation of trypsin in protease cascades contributing to tumor invasiveness.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12142374

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  17 in total

1.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

2.  SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.

Authors:  Kuo-Cheng Huang; Andrew Evans; Bryan Donnelly; Tarek A Bismar
Journal:  Pathol Oncol Res       Date:  2016-10-13       Impact factor: 3.201

3.  Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.

Authors:  Oliver Patschan; Shahrokh F Shariat; Daher C Chade; Pierre I Karakiewicz; Raheela Ashfaq; Yair Lotan; Kristina Hotakainen; Ulf-Håkan Stenman; Anders Bjartell
Journal:  World J Urol       Date:  2011-07-08       Impact factor: 4.226

4.  Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins.

Authors:  Benjamin F Mann; John A Goetz; Michael G House; C Max Schmidt; Milos V Novotny
Journal:  Mol Cell Proteomics       Date:  2012-03-05       Impact factor: 5.911

5.  Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development.

Authors:  Ulf-Håkan Stenman
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

6.  Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosis.

Authors:  Felix Lu; Jason Lamontagne; Angela Sun; Mark Pinkerton; Timothy Block; Xuanyong Lu
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

7.  SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.

Authors:  Danyelle Winchester; Luisel Ricks-Santi; Tshela Mason; Muneer Abbas; Robert L Copeland; Desta Beyene; Emmanuel Y Jingwi; Georgia M Dunston; Yasmine M Kanaan
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

8.  Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions.

Authors:  Sari Räty; Juhani Sand; Henrik Alfthan; Caj Haglund; Isto Nordback
Journal:  J Gastrointest Surg       Date:  2004 Jul-Aug       Impact factor: 3.452

9.  A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer.

Authors:  Hatem A El-mezayen; Fatheya M Metwally; Hossam Darwish
Journal:  Tumour Biol       Date:  2013-11-13

10.  A two-step toward personalized therapies for prostate cancer.

Authors:  Andrew S Goldstein; Yang Zong; Owen N Witte
Journal:  Sci Transl Med       Date:  2011-03-02       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.